SAN FRANCISCO—A blood test that identifies abnormal epigenomic and genomic signatures associated with pancreatic cancer detected 68% of cases of early-stage disease in a case-control study.
“Our noninvasive test ... demonstrates excellent performance in identifying pancreatic cancer from a simple blood draw and represents the first high-accuracy epigenomic test for detection in high-risk patients,” said Anna Bergamaschi, PhD, the vice president of product development at